Resultados da pesquisa - Portal para modelos de dados médicos (portal MDM)

Filtrar os resultados da pesquisa
Selecionar modelos de dados

Modelos de dados selecionados

Deve ter sessão iniciada para selecionar vários modelos de dados e para os transferir ou analisar.

1099 Resultados da pesquisa.

Eligibility Non-Hodgkin's Lymphoma NCT00076349

- 03/11/2016 - 1 Formulário, 2 Grupos de itens, 10 Elementos de dados, 1 Idioma

Grupos de itens: Inclusion Criteria, Exclusion Criteria

SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL); ODM derived from: https://clinicaltrials.gov/show/NCT00076349

Eligibility Non-Hodgkins Lymphoma NCT00054834

- 03/11/2016 - 1 Formulário, 1 Grupo de itens, 16 Elementos de dados, 1 Idioma

Grupo de itens: Criteria

Study of 90Y-hLL2 to Treat Non-Hodgkin's Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00054834

Eligibility Myeloid Leukemia, Chronic, Chronic-Phase NCT00510926

- 30/10/2016 - 1 Formulário, 2 Grupos de itens, 18 Elementos de dados, 1 Idioma

Grupos de itens: Inclusion Criteria, Exclusion Criteria

Exploratory Study of IMATINIB High Dose in Intermediate Risk Chronic Myeloid Leukemia in Chronic Phase; ODM derived from: https://clinicaltrials.gov/show/NCT00510926

Eligibility Myeloid Leukemia NCT00114764

- 29/10/2016 - 1 Formulário, 1 Grupo de itens, 11 Elementos de dados, 1 Idioma

Grupo de itens: Criteria

Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML); ODM derived from: https://clinicaltrials.gov/show/NCT00114764

Eligibility Multiple Myeloma NCT00661544

- 26/10/2016 - 1 Formulário, 2 Grupos de itens, 13 Elementos de dados, 1 Idioma

Grupos de itens: Inclusion Criteria, Exclusion Criteria

Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients; ODM derived from: https://clinicaltrials.gov/show/NCT00661544

A. Disease and general conditions of the aftercare Questionnaire for aftercare ABC study - A. Disease and general conditions of the aftercare Questionnaire for aftercare

- 26/10/2016 - 1 Formulário, 10 Grupos de itens, 85 Elementos de dados, 1 Idioma

Grupos de itens: therapy blood cancer, Aftercare condition, Period aftercare, Medical Examination, medical support, Supportive care, relapse blood cancer, symptoms relapse blood cancer, Medical Examination Relapse blood cancer, therapy Relapse blood cancer

Study part: A. Disease and general conditions of the aftercare Questionnaire for aftercare ABC Study. Aftercare pattern in adult patients with blood cancer and blood cancer early stage: Impact on health related endpoints, quality of life and health resource use. University clinic essen, (Klinik für Hämatologie Uniklinik Essen, UKE), department hematology. Permission granted by Claudia Ose.

Eligibility Multiple Myeloma NCT00459069

- 26/10/2016 - 1 Formulário, 2 Grupos de itens, 14 Elementos de dados, 1 Idioma

Grupos de itens: Inclusion Criteria, Exclusion Criteria

The Use of Dendritic Cell/Tumor Fusions as a Novel Tumor Vaccine in Patients With Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT00459069

Eligibility Multiple Myeloma NCT00622336

- 26/10/2016 - 1 Formulário, 2 Grupos de itens, 18 Elementos de dados, 1 Idioma

Grupos de itens: Inclusion Criteria, Exclusion Criteria

A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT00622336

Eligibility Multiple Myeloma NCT00427765

- 25/10/2016 - 1 Formulário, 2 Grupos de itens, 15 Elementos de dados, 1 Idioma

Grupos de itens: Inclusion Criteria, Exclusion Criteria

Busulfan Plus Melphalan Conditioning Regimen for Lymphoid Malignancies or Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT00427765

Eligibility Multiple Myeloma NCT00424047

- 25/10/2016 - 1 Formulário, 2 Grupos de itens, 14 Elementos de dados, 1 Idioma

Grupos de itens: Inclusion Criteria, Exclusion Criteria

A Study of Lenalidomide Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Patients With Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT00424047

Eligibility Multiple Myeloma NCT00337506

- 25/10/2016 - 1 Formulário, 2 Grupos de itens, 19 Elementos de dados, 1 Idioma

Grupos de itens: Inclusion Criteria, Exclusion Criteria

Velcade Combined With High-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT00337506

Eligibility Multiple Myeloma NCT00287872

- 25/10/2016 - 1 Formulário, 1 Grupo de itens, 20 Elementos de dados, 1 Idioma

Grupo de itens: Criteria

Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT00287872

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.